Drug Profile

Autologous chondrocyte implantation - Ocugen

Alternative Names: MDNT01; NeoCart

Latest Information Update: 26 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Histogenics Corporation
Developer Histogenics Corporation; Ocugen
Class Cell therapies
Mechanism of Action Chondrocytes replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase III Cartilage disorders

Most Recent Events

23 Jun 2025 OrthoCellix plans to submit BLA to US FDA for Cartilage disorders
23 Jun 2025 Ocugen plans a phase III trial for Cartilage disorders in USA by the end of 2025
16 Dec 2022 Ocugen announces intention to file phase III IND application to US FDA for Cartilage disorders in late 2023 or early 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com